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Abstract
Adenocarcinoma of the oesophagus and gastro-oesophageal junction are rapidly increasing in
incidence and have a well described sequence of carcinogenesis: the Barrett's metaplasia-dysplasia-
adenocarcinoma sequence. During recent years there have been changes in the knowledge
surrounding disease progression, cancer management and histopathology specimen reporting.
Tumours around the gastro-oesophageal junction (GOJ) pose several specific challenges.
Numerous difficulties arise when the existing TNM staging systems for gastric and oesophageal
cancers are applied to GOJ tumours. The issues facing the current TNM staging and GOJ tumour
classification systems are reviewed in this article. Recent evidence regarding the importance of
several histopathologically derived prognostic factors, such as circumferential resection margin
status and lymph node metastases, have implications for specimen reporting. With the rising use of
multimodal treatments for oesophageal cancer it is important that the response of the tumour to
this therapy is carefully documented pathologically. In addition, several controversial and novel
areas such as endoscopic mucosal resection, lymph node micrometastases and the sentinel node
concept are being studied. We aim to review these aspects, with special relevance to oesophageal
and gastro-oesophageal cancer specimen reporting, to update the surgical oncologist with an
interest in upper gastrointestinal cancer.
Background
In the Western world, distal oesophageal and gastro-
oesophageal adenocarcinoma is increasing in incidence
faster than any other type of gastrointestinal cancer [1].
During recent years there has been an increase in the
understanding of these tumour types and this has impli-
cations for the histopathologist and surgical oncologist.
The prognosis for patients with established cancer
remains poor. However, with the increasing use of surveil-
lance to monitor the progression of Barrett's oesophagus
there is the potential for diagnosis and treatment at an ear-
lier stage. The well defined carcinogenesis sequence of
metaplasia-dysplasia-adenocarcinoma lends itself well to
surveillance endoscopy.
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There are many studies indicating that hospitals which
manage large numbers of patients with upper gastrointes-
tinal cancer have better outcomes [2-4], although not all
evidence supports this view [5]. Upper gastrointestinal
cancer services in the UK are being streamlined and reor-
ganised with the development of hospital specialist multi-
disciplinary teams and regional cancer networks [6,7]. It is
recommended that surgical resection for oesophagogas-
tric cancer is performed in cancer centres serving a popu-
lation of at least 1 million and containing all necessary
multidisciplinary services. Although these studies favour-
ing centralisation have largely assessed factors such as
resection rates, postoperative morbidity and mortality
and patient survival, there is also evidence that the quality
of pathological reporting is improved [2]. Close links
between the upper gastrointestinal surgeon, gastroenter-
ologist, medical oncologist, histopathologist and other
members of the multidisciplinary team are essential in
improving outcomes in oesophageal cancer.
The work load of the specialist gastrointestinal patholo-
gist is increasing, especially in the assessment of oesopha-
geal resection specimens and endoscopic biopsy
reporting. There are many reasons for this increase:
• The numbers of patients participating in Barrett's
oesophagus surveillance programmes is increasing. A par-
ticularly controversial area is the designation of high
grade dysplasia (HGD).
￿ Tumours around the gastro-oesophageal junction,
which are rapidly increasing in incidence, pose several
specific problems to the histopathologist.
￿ As with other tumour sites, standardisation and an
emphasis on quality and completeness of pathological
reporting have become mandatory. There is a need for
pathologists to comply with the criteria in the minimum
dataset for reporting oesophageal cancer specimens.
￿ In some units the pathologist has a role in the assess-
ment of the resected specimen immediately after surgical
excision.
￿ Newer evidence on the importance of several his-
topathological prognostic factors, including circumferen-
tial resection margin status and lymph node metastases,
will have special implications for specimen reporting.
￿ With the rising rates of multimodal treatments for
oesophageal cancer the pathologist will have an increas-
ing role in documenting the response of the tumour to
this therapy.
￿ The issues of endoscopic mucosal resection (EMR),
lymph node micrometastases and the sentinel node con-
cept have the potential to expand the scope of the his-
topathologist.
We aim to review these aspects, with special relevance to
oesophageal and gastro-oesophageal cancer specimen
reporting, to update the surgical oncologist with an inter-
est in upper gastrointestinal cancer.
Endoscopic biopsies
Accurate assessment of endoscopic biopsy material is cru-
cial in the assessment of patients with Barrett's oesopha-
gus, oesophageal epithelial dysplasia and
adenocarcinoma. The British Society of Gastroenterology
(BSG) has recently published guidelines for the diagnosis
and management of Barrett's columnar-lined oesophagus
[8]. More biopsies are being examined due to the increase
in number of patients enrolled on endoscopic surveil-
lance programmes. Accurate classification into these diag-
nostic categories often requires multiple biopsies,
especially in high-grade dysplasia (HGD). The Seattle
group recommend four quadrant biopsies for every 2 cm
interval of Barrett's change identified at screening endos-
copy [9]; this is increased to four quadrant biopsies every
1 cm interval in cases of follow-up of Barrett's dysplasia. A
thorough review of the current pathological aspects of
these pre-malignant changes is beyond the scope of this
review (for recent review see [10]). However, the contro-
versy surrounding Barrett's dysplasia, especially HGD,
deserves a mention.
Barrett's dysplasia
Dysplasia is defined as unequivocal neoplastic transfor-
mation of the epithelium, strictly confined within the
basement membrane of the gland from which it arises
[11]. There is frequent disagreement between the classifi-
cation of HGD and intra-mucosal carcinoma [12]. The
WHO recommend the use of high grade intra-epithelial
neoplasia to cover both HGD and carcinoma in-situ to try
to increase inter-observer agreement, however in the UK
dysplasia is still in use. Changes in the epithelial cells
include lack of maturation towards the surface, variation
in nuclear size and shape, nucleolar enlargement,
increased cytoplasmic ratio, hyperchromasia and presence
of abnormal mitoses. Architectural changes seen in dys-
plasia include stratification of nuclei with loss of the nor-
mal basal location. Barrett's dysplasia is classified into
either indefinite for dysplasia, low grade dysplasia (LGD)
or HGD by the degree of cellular and architectural changes
[13,14]. A diagnosis of indefinite for dysplasia is made
when histological features suggestive of dysplasia are seen
but the presence of inflammation makes it impossible to
distinguish confidently between reactive changes and true
dysplasia. The BSG guidelines recommend prompt fol-World Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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low-up and treatment of cases of indefinite dysplasia with
acid suppression followed by extensive endoscopic biop-
sies [8]. Further endoscopy and biopsies should then be
taken after six months and if all fail to show definite evi-
dence of dysplasia the patient can return to routine fol-
low-up. LGD should be managed by acid suppression for
eight to twelve weeks followed by repeat endoscopy and
extensive re-biopsy. If the LGD persists surveillance
should be six monthly. If regression occurs on two consec-
utive examinations surveillance intervals may be
increased to two to three yearly.
As a consequence of the subtle cytological changes from
LGD to HGD, previous studies have shown that there are
marked intra-observer and inter-observer variations in the
classification of the degree of dysplasia [15]. The clinical
application of these studies is to emphasize the need of a
second opinion from an experienced gastrointestinal his-
topathologist in difficult cases, especially when the dis-
tinction is clinically important and will change
therapeutic management [16]. This may require a further
endoscopy for collection of additional material using the
'Seattle' protocol to ensure sufficient tissue for accurate
designation is available and to minimise the risk of miss-
ing an occult adenocarcinoma [9]. Unfortunately there are
at present no reliable immunohistochemical markers
available to distinguish between reactive changes and dys-
plasia. When there is consensus among three pathologists
on the designation of LGD, then the progression to HGD
or carcinoma appears to be substantial [17].
Appropriate care of patients with HGD in the setting of
Barrett's oesophagus relies heavily on the accuracy of
reporting the degree of dysplasia [18]. Early studies have
shown that HGD was associated with up to a 73% risk of
undetected adenocarcinoma on subsequent oesophagec-
tomy specimens [19,20]. There are conflicting results on
whether the risk of progression is related to the extent of
HGD present. In one study, the risk was unrelated to the
amount of HGD present [21]; therefore even a small area
should not be discounted. However, in another study
multifocal HGD had a higher risk of progression to malig-
nancy than unifocal HGD [22]. This may be due to factors
relating to genomic instability and clonal expansion [23].
Treatment options for HGD are controversial and range
from intense endoscopic surveillance, endoscopic ablative
therapy, EMR and oesophagectomy [24]. In those unfit for
surgery endoscopic ablation or EMR should be consid-
ered. In Japan, EMR is the standard treatment for early
neoplasms but these tend to be squamous cell carcinomas
which have many differing characteristics to adenocarci-
nomas. The recent BSG guidelines recommend
oesophagectomy in a specialised unit in patients consid-
ered fit for surgery.
Standardisation of oesophageal resection specimen 
reporting
The histopathologist has an important role in ensuring
quality and a consistent approach to pathological report-
ing. An accurate histopathology report is essential for pro-
viding detailed staging of the primary tumour, elucidating
prognostic information and for guiding optimal clinical
management decisions. Audit, research, cancer registry
data and other epidemiological studies rely heavily on the
accuracy of this information. Upper gastrointestinal sur-
geons and clinicians have demanded an increase in the
quality and quantity of information from the pathologist.
The Royal College of Pathologists have published guide-
lines on the standards of oesophageal resection specimen
reporting which include a proforma detailing the Mini-
mum Dataset requirements [25]. A similar 'best practice'
report has been published by the Association of Clinical
Pathologists (ACP) [26] and the College of American
Pathologists has its own guidelines [27]. Despite this
guidance the quality of pathological reporting has been
variable [28,29]. Missing data items from an audit of
oesophageal resection specimens reported in 2004
included key data (% missing) such as tumour differenti-
ation (14%), proximal margin involvement (17%), distal
margin involvement (19%), completeness of resection
(48%) and circumferential margin involvement (48%)
[29]. It is hoped, as with other cancer types, that the
increased use of proformas will increase quality and
standardisation of specimen reporting [28]. The centrali-
sation of oesophageal surgery services in one region
resulted in a significant improvement in oesophageal
resection specimen reporting [2].
The resected specimen: problems around the gastro-
oesophageal junction (GOJ)
Tumours around the gastro-oesophageal junction (GOJ)
have become commoner in recent decades [1,30,31] and
present particular challenges. Classification systems for
GOJ tumours have been devised [32,33], but sadly they
have not been widely adopted into routine clinical prac-
tice in the UK. Sub-classification is not a part of the cur-
rent requirements of the Royal College of Pathologists
Minimum Dataset for reporting oesophageal cancer [25].
Here a carcinoma is classified as oesophageal if more than
half of the tumour is above the gastro-oesophageal junc-
tion. Histopathologists sometimes find the distinction
between oesophageal and gastric tumours surrounding
the gastro-oesophageal junction difficult. This is usually
defined endoscopically as the upper limit of the gastric
rugal folds. In large tumours the gastro-oesophageal junc-
tion may be obliterated making it impossible to comment
on whether the tumour is mainly above or below it. In
such cases the anatomical site (recognised by the perito-
neal reflection at the junction of the oesophagus andWorld Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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greater curve of the stomach) of the gastro-oesophageal
junction may be of help [26]. The histopathologist may
look for the presence of columnar lined oesophagus
above the tumour that would be suggestive of an oesopha-
geal origin, especially if associated with dysplasia, or for
gastric dysplasia suggesting gastric origin. However, the
definition, location and extent of the gastric cardia and
GOJ are controversial in much of the medical literature.
This can make it harder to compare and contrast previ-
ously published studies including different patient popu-
lations with heterogeneous tumour types.
The UICC/AJCC classification systems rely on the ana-
tomical location of the epicentre or predominant mass of
the tumour to decide whether the tumour is oesophageal
or gastric in origin [34]. With the increasing proportion of
these cancers, especially types which straddle the GOJ
with equal proportions on each side, it has become appar-
ent that this system is inadequate. The Siewert classifica-
tion system was approved following a consensus
conference of the International Society for Diseases of
Esophagus (ISDE) meeting in 1995 [35] and is the most
widely adopted classification system. GOJ tumours are
anatomically classified into three sub-types depending on
distance from the cardia, which is defined as the proximal
end of the typical longitudinal gastric mucosa folds [33].
According to the authors, there are key differences in epi-
demiological, clinical and pathological characteristics
between these tumour subtypes and the classification sys-
tem can also aid planning of surgical treatment (Table 1).
These tumour sub-types also differ in their predilection
for lymph node metastases to the mediastinal and
abdominal lymph node stations (Figure 1). Siewert's clas-
sification system is recommended for use by the British
Society of Gastroenterology in the published Guidelines for
the management of oesophageal and gastric cancer as 'it is uni-
form, allows data comparison from different centres, and
is important for the stratification of patients in prospec-
tive studies' [16]. Criticisms of the Siewert system are 1)
that it unnecessarily complicates the assessment of these
tumours; 2) it is difficult to assign some tumours because
of their size and overlapping nature and 3) that some
authors prefer to classify distal oesophageal and gastro-
esophageal junction tumours as one clinical entity as they
have found similar distributions of lymph node metas-
tases and survival [36-38].
Problems with the current TNM staging systems
The existing TNM staging system also has some deficits
[39], which include the following:
￿ It is based primarily on data from patients with squa-
mous cell carcinoma of the middle and upper oesophagus
￿ There is confusion regarding whether the oesophageal or
gastric TNM systems should be used for GOJ tumours
￿ Lymph node involvement beyond the regional lymph
nodes is considered metastatic disease (M1)
￿ The number of positive lymph nodes has been shown to
be a strong prognostic factor by many authors, however,
this is not apart of the current TNM system
Currently there is confusion about whether the gastric or
oesophageal staging systems should be used for the histo-
logical reporting of gastro-oesophageal junction tumours.
Due to this confusion a tumour at the GOJ could be clas-
Table 1: Tumour around the gastro-oesophageal junction: classification system and principal differences. (Information taken from [33, 
42, 110])
GOJ subtypes Type I (Adenocarcinoma of 
distal oesophagus)
Type II (True cardia 
carcinoma)
Type III (Sub-cardial 
carcinoma)
Endoscopic criteria Tumour mass arises 1 to 5 cm 
above the endoscopic cardia
Tumour mass arises 1 cm above to 
2 cm below the endoscopic cardia
Tumour mass arises 2 to 5 cm 
below the area of the endoscopic 
cardia
Differing Characteristics • Male predominance
• Arise in association with Barrett's 
oesophagus (80%)
• More likely to have hiatus hernia 
or history of GORD
• More similarities to Type III 
tumours than Type I
• Barrett's mucosa identified in 10%
• Barrett's mucosa identified in only 
2%
• 60% have a diffuse growth pattern 
and 70% undifferentiated
Lymph node metastases To mediastinal and abdominal 
lymph node stations
Mainly to abdominal lymph node 
stations
Mainly to abdominal lymph node 
stations
Precursor lesions Barrett's oesophagus Possible short segment Barrett's 
oesophagus or IM at the gastric 
cardia
Helicobacter pylori and IM of the 
subcardia region
Optimal surgical treatment Transthoracic or transhiatal 
oesophagectomy
Controversial; may include either 
extended total gastrectomy or 
transthoracic or transhiatal 
oesophagogastrectomy
Extended total gastrectomy
IM = intestinal metaplasia, GORD = gastro-esophageal reflux diseaseWorld Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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sified as oesophageal by the surgeon but gastric by the his-
topathologist or vice versa, especially when cases are not
discussed at a preoperative multidisciplinary meeting.
Usually, Type I adenocarcinomas are staged as oesopha-
geal cancer and Type III as gastric cancer. Type II adenocar-
cinomas are staged as oesophageal cancer by some
authors and as gastric by others. This is not ideal as there
are significant differences between the gastric and
oesophageal TNM staging systems in all three TNM cate-
gories (Table 2). There are major differences in the pT
stages between the two systems, but the most significant
differences are in the pN staging category. In oesophageal
cancer nodal involvement is merely classified as nodal
positive (pN1) and nodal negative (pN0), irrespective of
the number of lymph nodes involved. In comparison, for
gastric cancer TNM staging, the pN category is sub-classi-
fied according to the number of involved nodes: pN1 (1–
6 positive nodes), pN2 (7–15 positive nodes) and pN3
(>15 positive nodes). Metastatic lymph nodes to the coe-
liac axis are classified as systemic spread (pM1a) in the
oesophageal system, whilst they are classified as regional
in the gastric staging system. Therefore, the classification
of Siewert type II tumours with positive celiac lymph
nodes is controversial. Similarly, metastases to the supra-
diaphragmatic nodes or to the nodes of the lower medi-
astinum are considered 'non-regional' in gastric cancer,
and are classified as distant metastases (pM1) in type II
and type III junctional tumours. Consequently there have
been calls for tumours around the GOJ to have a separate
TNM staging system [40]; however this remains to be
designed or approved by the UICC/AJCC.
Histopathological prognostic markers in oesophageal and 
GOJ cancer
The most important predictors of prognosis appear to be
the overall TNM stage [34], completeness of resection (R
The lymph node stations surrounding the oesophagus and upper stomach are shown Figure 1
The lymph node stations surrounding the oesophagus and upper stomach are shown. Type I, II and III gastro-oesophageal 
tumours vary in their predilection for involvement of different lymph node stations in the mediastinum and abdomen. Please 
note that the information about metastatic spread to the mediastinal lymph nodes in Type III tumours is limited as surgical 
resection does not normally include these nodes. Information on percentage of lymph node metastases taken from Dresner et 
al [110] and Ichikura et al [121].World Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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classification) [41,42] and the presence of lymph node
metastases [43]. Other important histopathological fac-
tors are summarised in Table 3. Although newer molecu-
lar based markers are being assessed to see if they can be
used to predict prognosis, none are in routine clinical use
and they are beyond the scope of this article (for recent
review see [44]).
Residual disease classification and resection margin involvement
The residual tumour classification (Table 4) is one of the
strongest prognostic factors after surgical resection
[41,42]. It is classified into: R0, complete microscopic and
macroscopic resection; R1, residual microscopic disease
and R2, residual macroscopic disease (Table 4) [45]. Both
the pathologist and the surgeon have roles in defining the
R status during and after surgery.
The circumferential resection margin (CRM) is defined as
the surgically cut surface of the connective tissues that
encase the oesophagus. Presence of tumour within 1 mm
of this resection margin is classified as evidence of
involvement. Although it has long been established that
involvement of the proximal or distal resection margin is
a poor prognostic factor [46,47], the relevance of the CRM
status has been unclear and few studies have addressed
this issue. However, the increased awareness of the CRM
status in rectal cancer has inspired investigation in
oesophageal cancer. In rectal cancer surgery, the patholog-
ical reporting of CRM is important as its status predicts
risk of local disease recurrence and reduced survival
[48,49]. It is routinely reported in all rectal resection spec-
imens and involvement is often an indication for post-
operative chemotherapy and/or radiotherapy.
Circumferential resection margin (CRM) involvement and 
oesophageal cancer reporting (Table 5)
An initial study by Sagar et al [50] in 1993 assessed 50
patients undergoing oesophagectomy and found that can-
cer involvement of the CRM was associated with increased
risk of local disease recurrence and significantly reduced
2-year survival. More recently, Dexter et al., studied 135
patients who underwent oesophagogastrectomy [51],
they included only the patients who had underwent a
potentially curative procedure, excluding patients with
other margin involvement, T4 tumours, M1a or M1b dis-
ease and palliative resections. The rate of CRM involve-
ment in their study was 47%. Survival was significantly
reduced in patients with CRM involvement who would
have been otherwise considered to have had a potentially
curative resection. CRM involvement was also an inde-
pendent predictor of survival on multivariate analysis.
They also observed that when they stratified patients into
Table 3: Histopathological prognostic factors after surgical 
resection of oesophageal cancer
Factor Reference
Residual (R) tumour classification * [41, 42]
Proximal and distal margin involvement [46, 47]
Circumferential resection margin involvement [50, 51, 56]
Tumour invasion (T stage) [42, 68, 111, 112]
Lymph node metastases [42, 43, 68]
Vascular invasion [53, 113, 114]
Lymphatic vessel invasion (LVI) [61-63]
Perineural invasion [115]
Tumour length [43, 116]
Tumour differentiation [117, 118]
Histological subtype [65]
* R0 complete microscopic and macroscopic resection; R1 residual 
microscopic disease; R2 residual macroscopic disease
Table 2: Comparison between the oesophageal and gastric TNM staging [34]
Oesophageal staging Gastric staging
T Stage T0 No evidence of primary tumour T0 No evidence of primary tumour
Tis Carcinoma in situ Tis Carcinoma in situ
T1 Tumour invades lamina propria or submucosa T1 Tumour invades lamina propria or submucosa
T2 Tumour invades muscularis propria T2a Tumour invades muscularis propria
T3 Tumour invades adventitia T2b Tumour invades subserosa
T4 Tumour invades adjacent structures T3 Tumour penetrates serosa (visceral peritoneum) 
without invasion of adjacent structures
T4 Tumour invades adjacent structures
N Stage NX Regional lymph nodes cannot be assessed NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases N0 No regional lymph node metastases
N1 Regional lymph node metastases N1 Metastases in 1 to 6 regional lymph nodes
N2 Metastases in 7 to 15 regional lymph nodes
N3 Metastases in more than 15 regional lymph nodes
M Stage MX Distant metastases cannot be assessed MX Distant metastases cannot be assessed
M0 No distant metastases M0 No distant metastases
M1a Metastases to coeliac or cervical lymph nodes M1 Distant metastases
M1b Other distant metastasesWorld Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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low and high nodal metastatic burden (< or > 25%
involved lymph nodes), the effect of CRM status on sur-
vival was more significant in patients with a low ratio of
involved metastatic lymph nodes. A recent report sug-
gested that even in patients with T3 tumours and a low
percentage of lymph node metastases (<25%) there is an
improved prognosis if the CRM were negative [52].
In a follow-up study with larger patient numbers carried
out by the same group [53], CRM was still a prognostic
factor on univariate analysis but lost its significance as an
independent prognostic variable. However in this study,
the R classification (which included CRM status) was an
independent prognostic factor, together with nodal status
and vascular invasion.
Not all studies have shown a positive CRM to predict a
poor prognosis in oesophageal cancer. Khan et al., [54]
observed 329 patients undergoing resection and found no
difference in survival between patients with or without
CRM involvement. Although the reasons for the differ-
ence are not entirely clear, the surgical technique in the
Khan study favoured extensive mediastinal dissection. For
example, in this study only T3 tumours (tumour invading
the adventitia) had evidence of CRM involvement. In the
Dexter study there were cases of T2 tumours (tumours
invading muscularis propria) involving the CRM [51],
suggesting that less radical surgery was performed. In sup-
port of this, the study by Khan et al., had the lowest rate of
CRM involvement (20%). Therefore the prognostic
impact of CRM status may be related to the completeness
of the mediastinal dissection. A similar situation is
present in rectal cancer surgery, where the prognostic
effect of CRM involvement is lessened following more
radical surgical resection [55].
Although Khan et al., questioned whether CRM status
should be an essential part of oesophageal resection spec-
imen reporting [54], the majority of studies support the
notion that CRM involvement is a significant prognostic
factor [50-53,56]. Moreover, three of these studies have
shown it to be a significant independent predictor of sur-
vival on multivariate analysis [51,52,56]. It would seem
sensible to continue to record the involvement of the
CRM in oesophageal resection specimen reports.
CRM status as a marker of quality of surgery
It is important that the anatomy of the oesophagus is
understood, especially as regards to the surrounding struc-
tures in the thorax. The CRM includes the whole circum-
ference at and just above the gastro-oesophageal junction,
but more proximally it is concentrated anteriorly and pos-
teriorly with pleura on the lateral aspects. The pleural sur-
faces are not a true CRM and the significance of tumour
involvement at this site is uncertain as there have been no
large studies examining this [57]. It can be difficult to
identify the pleura on the resected specimen but this diffi-
cultly is removed if the surgeon marks the pleural surface
or if the fresh resected specimen is seen and discussed
together by both surgeon and pathologist.
Table 5: Studies assessing the prognostic impact of CRM status in oesophageal cancer
Author, Date No. Country Type study Tumour % CRM 
involvement
Significance on 
univariate 
survival
Significant on 
multivariate 
survival
Sagar, 1993 [50] 50 UK R Adeno, SCC 40% Yes (p < 0.05) Not tested
Saha, 2001 [56] 59 UK R Adeno Unknown Yes (p < 0.01) Yes (p < 0.05)
Dexter, 2001 [51]* 135 UK P Adeno, SCC 47% Yes (p < 0.015) Yes (p = 0.013)
Zafirellis, 2002 [53]* 156 UK P Adeno, SCC 42% Yes (p < 0.0001) Not significant
Khan, 2003 [54] 329 UK R Adeno, SCC 20% No (p = 0.57) Not applicable
Roh, 2004 [119] 59 Korea R SCC 44% Yes (p = 0.003) Not tested
Griffiths, 2006 [52] 249 UK R Adeno, SCC 32% Yes (p = 0.0001) Yes (p = 0.007)
R = retrospective, P = prospective, Adeno = adenocarcinoma, SCC = squamous cell carcinoma, *These two studies from the same research group 
include some of the same patients.
Table 4: Residual (R) tumour classification system [45]
R Classification Meaning
R0 Complete resection of microscopic and macroscopic disease
R1 Incomplete resection; residual microscopic disease
R2 Incomplete resection; residual macroscopic diseaseWorld Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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In rectal surgery, a large intact capsule of mesorectum sur-
rounding the resected cancer specimen has been suggested
as a marker of good quality surgery [58,59]. However,
there are important anatomical differences between the
pelvis and the mediastinum (Figure 2). The oesophagus
lacks a serosal layer, so that tumours originating in the
(a) MRI of the pelvis showing the ample surrounding mesorectal tissue and fascia, in comparison to (b) which shows a CT  image of the mediastinum showing how little tissue separates the oesophagus from important unresectable structures such as  the aorta and heart Figure 2
(a) MRI of the pelvis showing the ample surrounding mesorectal tissue and fascia, in comparison to (b) which shows a CT 
image of the mediastinum showing how little tissue separates the oesophagus from important unresectable structures such as 
the aorta and heart. (c) Transverse cut sections of anterior resection specimen for rectal cancer (note how much more sur-
rounding tissue there is compared with the oesophageal specimen) (d) Transverse cut sections of oesophageal resection spec-
imen; this method of sectioning allows direct comparison with the pre-operative staging.World Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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oesophagus can easily spread into several important struc-
tures (pericardium, heart, great vessels, trachea and lung).
The majority of these adjacent structures cannot be sacri-
ficed and resected en-bloc. In addition, there is no specific
fascial boundary equivalent to the mesorectal or Denon-
villier's fascia present in the pelvis. CRM involvement in
the oesophageal cancer specimen may therefore be much
more a consequence of advanced tumour stage rather
than the skill of the surgeon in carrying out a complete
resection. Nevertheless, involvement of the CRM may be
an indicator of the quality of pre-operative staging. At
present most pathologists open oesophagogastric resec-
tions longitudinally, with or without pinning out of the
fresh specimen, for fixation [26]. This does not allow good
comparison with radiological imaging. In rectal tumours
transverse slices through the tumour are advocated to
allow comparison with MRI. If the quality of oesoph-
agogastric cancer preoperative staging is to be studied
transverse slices through the tumour are recommended.
The fact that some surgeons remove lymph nodes from
the main specimen and submit them separately prevents
assessment of the CRM; this should be discouraged. All of
the information acquired by separate dissection of the
lymph nodes should be available from thorough,
although time consuming, macroscopic examination of
the fixed specimen. Some feel that separate dissection of
the lymph nodes yields a higher lymph node count com-
pared to lymph node harvesting by the histopathologist.
However serial slicing with narrow slice width and careful
examination of all attached fat, both by palpation and vis-
ually, should result in a high lymph node yield. It may be
useful to take a macroscopic photograph of the sliced
specimen to compare with preoperative imaging.
Serosal invasion
Serosal invasion is an important prognostic marker in
many gastrointestinal malignancies [57]. Gastro-oesopha-
geal junctional tumours may invade the serosal surface of
the proximal stomach with or without CRM involvement
of the lower oesophagus. Assessment for serosal invasion
in this area is included in the oesophageal minimum data-
set as there is strong evidence that it is a poor prognostic
factor in gastric cancer [57]. However no studies have
been performed to prove this is the case in oesophageal
tumours [57].
Vascular and lymphatic vessel invasion (LVI)
Vascular invasion is known to be a strong prognostic fac-
tor and is included in the oesophageal minimum dataset.
However, it is not included in the gastric minimum data-
set [60], which further highlights the differences between
the two proformas. Recent evidence has shown that LVI is
a strong prognostic factor in both squamous cell carcino-
mas and adenocarcinomas of the oesophagus [61-63]. In
a study focusing on GOJ adenocarcinomas it was found to
be an independent prognostic factor [63]. Interestingly in
this large study, it appeared to be more prognostic in type
II and III GOJ tumours, compared with type I cancers. This
adds to the argument that there are biological differences
between these tumour types.
Lymph node metastases
The presence of lymph node metastases is often the most
significant independent factor on multivariate analysis
[42,43,64,65]. However, there is no consensus regarding
minimum numbers of lymph nodes to be included in a
curative resection for accurate pathological staging or on
the sampling technique used. The minimum dataset for
oesophageal carcinoma does not comment on how to
sample lymph nodes [25]. The minimum dataset for gas-
tric cancers states that the lymph node should be cut
through its greatest diameter and one half taken for micro-
scopy [60]. However, this sampling technique has the
potential of missing metastatic deposits and it is best prac-
tice to examine the whole node microscopically unless it
is clearly replaced by tumour [26].
The current (2002) UICC guidelines recommend a mini-
mum examination of 6 lymph nodes to classify a patient
N0 [66]. However this falls short of the 15 recommended
by the consensus conference of the International Society
for Diseases of the Esophagus (ISDE) [67]. As mentioned
previously, the current oesophageal staging criteria simply
divide patients into lymph node metastases present (pN1)
and lymph node metastases absent (pN0). This system is
crude and does not take into account the total number of
resected/examined nodes. There is strong evidence that a
lymph node ratio (number of nodes involved/number
nodes examined) may be a better system. The prognostic
significance of metastatic lymph node ratio has been
described in oesophageal adenocarcinoma in Western
patients (ratios of 0.2 and 0.3) [42,53,68], squamous cell
carcinoma in Western patients (ratio of 0.2) [64] and
squamous cell carcinoma in Japanese patients (ratio of
0.1) [69]. The differences in ratios for each of these studies
may reflect the differences in nodal yields obtained from
two-field oesophago-gastrectomy for adenocarcinoma
and three-field oesophago-gastrectomy for squamous cell
carcinoma. Noticeably in all these five studies the lymph
node ratio was of greater prognostic significance than the
N stage. As there is no consensus for the exact lymph node
ratio, it remains important for the pathologist to accu-
rately report the total number of involved nodes and the
total number examined. Also at present only one level of
each lymph node is examined microscopically. Further
studies researching the benefit of further levels are
required [70]; this may potentially yield additional prog-
nostic information, especially in patients who are initially
designated pN0 with a low yield of lymph nodes.World Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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In addition to a pure number based system, nodal
involvement in relation to the lymph node capsule (intra
or extracapsular) has recently been shown to be strongly
prognostic on multivariate survival analysis in oesoph-
agogastric adenocarcinoma [71,72]. The 5-year survival
for patients with intracapsular nodal involvement was
40.9% compared with only 18% with extracapsular
involvement [72].
Immunohistochemically detected lymph node micrometastases
Immunohistochemical techniques can identify microme-
tastases which are missed by standard haematoxylin and
eosin staining. Cytokeratin, a component of the cytoskel-
eton of epithelial cells, is not found in normal nodes ena-
bling monoclonal antibodies to certain cytokeratin
markers (such as AE1/AE3) to be used to detect microme-
tastases. These techniques may detect single tumour cells
or cell clusters in lymph nodes that have been staged as
tumour free on routine examination. The prognostic out-
come of the detection of micrometastases detected by
immunohistochemistry is controversial as some studies
have found an association with increased risk of tumour
recurrence and decreased survival [73-75], but others have
not [76,77]. The viability of these tumour cells and their
potential to form true metastases has been questioned. As
such, these techniques remain research tools and are not
currently used in daily clinical practice.
Sentinel node concept in oesophageal and GOJ cancer
The importance and clinical utility of the sentinel node
concept has been extensively evaluated in malignant
melanoma and breast cancer. It is being evaluated in gas-
trointestinal cancers [78], including oesophageal cancer.
The sentinel node concept relies on two assumptions.
Firstly, lymphatic metastases from a solid tumour follow
a predictable course and that there is always one node (the
'sentinel node') or group of nodes that is affected first. Sec-
ondly, metastases to other lymph nodes or lymph nodes
groups cannot occur without involvement of the sentinel
node. These assumptions remain to be conclusively
proven in the context of oesophagogastric cancer and
other confounding factors may exist, such as the possibil-
ity of 'skip' metastases [79] and the alteration of lym-
phatic flow due to 'blocked' nodes.
Initial feasibility studies have been performed in oesopha-
geal cancer [78,80]. The principal benefit of the sentinel
lymph node concept if validated in oesophageal cancer
surgery may be to permit tailoring the extent of the lym-
phadenectomy. The morbidity from extensive lym-
phadenectomy can be high; therefore, if the sentinel node
is not involved then patients could be spared more exten-
sive surgery. However, the complex and extensive lym-
phatic drainage of the oesophagus may make this
approach problematic and its ultimate role is likely to be
limited. In addition, the technique relies on accurate path-
ological examination of the sentinel node intra-opera-
tively which has its own drawbacks. The exact technique
has yet to be defined, but frozen sectioning, touch imprint
cytology and rapid immunohistochemistry are being eval-
uated. Until more extensive high quality prospective stud-
ies are performed in oesophageal cancer, the usefulness of
the sentinel node concept in this area remains uncertain.
Endoscopic mucosal resection (EMR)
Endoscopic mucosal resection (EMR) techniques are
being increasingly used for treatment and staging of
superficial early cancers of the oesophagus, especially in
Japan although Western centres are gaining experience
[81,82]. Although the precise indications for EMR have
not been established, in the oesophagus EMR may be cur-
ative for small superficial squamous cell carcinomas or
adenocarcinomas which are limited to the mucosa or lam-
ina propria [83]. HGD of the oesophagus can also be
treated with EMR techniques. The treatment of circumfer-
ential lesions is possible, but there is a high risk of subse-
quent stricture formation. The resected specimen must be
carefully examined in its entirety for accurate pathological
staging [84] and to allow future audit and preparation of
appropriate guidelines on the safe use of this technique.
The main problem with EMR is the lack of pathological
lymph node staging. The risk of lymph node metastases
increases with tumour penetration through the mucosa
and submucosa [84]. Based on the Japanese classification
of early neoplasia of the oesophagus a more comprehen-
sive staging system than TNM is suggested when reporting
such specimens. The recommended staging splits mucosal
involvement into three categories (m1: equivalent to
HGD with questionable invasion beyond the basement
membrane; m2: invasion of the lamina propria and m3:
invasion into but not through the muscularis mucosa)
and submucosal involvement into 3 categories (sm1:
invasion into the upper third of submucosa; sm2: inva-
sion into the middle third of submucosa and sm3: inva-
sion into the lower third of submucosa). Lymphovascular
invasion should be reported if present. As some series
report a high rate of incomplete resections with this tech-
nique, some authors advocate its use as a diagnostic and
staging tool rather than a therapeutic technique [82].
Multimodal therapy and implications for pathological 
specimen reporting
Multimodal therapy, in particular neo-adjuvant treatment
prior to surgical resection, is increasingly used in oesopha-
geal cancer. The aims of neo-adjuvant chemotherapy, with
or without radiotherapy, are to downstage or 'sterilise' the
primary to improve the likelihood of complete tumour
(R0) resection, reduce tumour recurrence, treat occult
micro-metastases and ultimately to improve overall sur-
vival. Although there is some evidence from randomisedWorld Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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controlled trials that neo-adjuvant therapy in addition to
surgery can prolong survival [85-88], there remains con-
siderable debate in the literature about the benefits of
therapy and the definitive regime has yet to be defined.
Other authors have found that multimodal therapy is
associated with an increased post-operative mortality
[88,89] and morbidity [90,91], especially sepsis related
complications, respiratory failure and adult respiratory
distress syndrome.
A pathological complete response (CR) occurs in less than
30% of patients who undergo surgery after preoperative
chemotherapy or chemo-radiotherapy [92-94]. Although
patients who achieve a CR appear to have a longer overall
survival [95-97] these results are mainly from sub-group
analysis and should be treated with some caution.
Classifying pathological response to multimodal therapy
In instances of a potential CR, knowledge of the precise
location of the tumour before neo-adjuvant therapy is cru-
cial to direct pathological sampling as the oesophagus
may look normal macroscopically. However, the precise
number of tumour blocks to take has yet to be clarified
and currently is at the discretion of the histopathologist.
Various architectural, nuclear and cytoplasmic changes in
tumour and non-tumour tissue have been described fol-
lowing neo-adjuvant chemotherapy [98]. In addition,
radiotherapy induced changes include fibrosis, tel-
angiectasia of submucosal vessels, bizarre nuclear appear-
ances in tumour and stromal cells and necrosis [99].
Mucin lakes and collections of keratin are considered to
represent areas where tumour has been present prior to
sterilisation by chemotherapy. Preliminary evidence sug-
gests that prominent acellular mucin pools in patients
who have received neo-adjuvant chemotherapy should
not be considered evidence of residual disease [100].
Immunohistochemistry using cytokeratin antibodies may
be required to identify residual tumour cells not readily
seen on haematoxylin and eosin staining.
There are a variety of different grading systems for meas-
uring residual tumour in oesophageal resection speci-
mens after preoperative chemotherapy, with or without
radiotherapy (Table 6) [101-103]. The Mandard et al., sys-
tem [103] would seem to be the most applicable because
it assesses residual tumour in relation to background
fibrosis, and this has been shown to be important in
oesophageal cancer. However, this system was not shown
to yield prognostic information in a recent study [98],
whereas the residual carcinoma status correlates signifi-
cantly with prognosis in several retrospective studies
[101,104]. It also uses a simple system of percentage of
residual tumour which is likely to be more reproducible.
However, none of these systems have been universally
accepted (Table 6).
With the increased interest in multi-modal therapy, how-
ever, the classification of pathological response is of
increasing importance to the histopathologist and sur-
geon. Proposals to revise the oesophageal cancer staging
Table 6: Classification systems to grade tumour response to neo-adjuvant chemo-radiotherapy
Reference, Name of classification system Details/definition
Mandard et al [103]; Tumour regression grade (TRG) TRG1 Complete pathological regression: absence of residual 
cancer and fibrosis extending through the layers of the 
oesophageal wall
TRG2 Presence of rare residual cancer cells scattered through 
the fibrosis
TRG3 Increase in the number of residual cancer cells, but fibrosis 
still predominant
TRG4 Showing residual cancer outgrowing fibrosis
TRG5 Absence of regressive changes
Chirieac et al [101]; Residual carcinoma status 0 No residual cancer
1 1% to 10% residual cancer
2 11%–50% residual cancer
3> 5 0 %  r e s i d u a l  c a n c e r
General rules for oesophageal cancer proposed by the 
Japanese Society for Esophageal Disease [120] *
Complete response Disappearance of the primary tumour in the postoperative 
specimen
Partial response Microscopic evidence of residual tumour in the 
postoperative specimen
Stable disease Less than 50% decrease or less than a 25% increase in 
tumour volume
Progressive disease No significant change in tumour mass or more than a 25% 
increase in tumour volume
*In addition to pathological assessment of the resection specimen, the designation to stable or progressive disease is by re-evaluation of the primary 
tumour by computed tomography and endoscopy 2 weeks after completion of CRT.World Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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system to accommodate the pathological response of the
tumour following preoperative chemo-radiotherapy have
recently been made [104]. The final pathological staging
in the cases treated with neo-adjuvant therapy should be
prefixed 'y' (for example, ypT2, ypN0, ypM0) [34].
Predictive factors for response to neo-adjuvant chemo-radiotherapy
There is great interest in evaluating predictive factors for
patient response to neo-adjuvant chemo-radiotherapy. An
accurate predictive factor would allow the targeting of
therapy to patients who are most likely to achieve a bene-
fit, while those that are unlikely to respond can avoid
potentially toxic therapy and receive earlier surgery.
A recent study has shown that patients with signet-ring
cell or mucinous histology on pre-treatment biopsies have
an improved response and better overall survival when
treated with neo-adjuvant chemo-radiotherapy [105].
This study compared 193 patients who were treated with
chemo-radiotherapy (5-Flurouracil, cisplatin and taxane
with 45 Gy radiotherapy in 25 fractions) followed by sur-
gery with 219 patients who had surgery alone. In the
patients who had surgery alone, the overall survival rate
was significantly worse if signet-ring or mucinous histol-
ogy was present. However, in the patients who were
treated with chemo-radiotherapy signet-ring or mucinous
histology predicted a better overall survival.
More sophisticated molecular techniques have been eval-
uated on pre-therapeutic biopsies in an attempt to find a
good predictive marker. Although, none of these are cur-
rently being used in routine clinical practice, the role of
the histopathologist in this regard is likely to increase in
the future.
Multidisciplinary meetings
The management of patients with oesophagogastric can-
cer should be discussed at all key points in the patient
journey at specialist multidisciplinary team (MDT) meet-
ings [106]. There is some evidence that MDT discussion is
associated with improved patient outcomes in oesopha-
geal cancer [107]. Stephens et al reported a lower opera-
tive mortality and improved 5-year survival in R0 resected
patients who were discussed at an MDT compared with
patients who underwent R0 resection by independent sur-
geons [107]. The management of patients with oesoph-
agogastric cancer is complex and involves input from
several clinical specialities. A forum in which to review the
histological slides may lead to alteration in the final path-
ological diagnosis [108], either due to specialist patholog-
ical review or by additional information provided by the
clinician. Regular communication between all specialities
at these meetings provides an opportunity to improve and
maintain the quality of pathological reporting. Recent evi-
dence has shown that MDT discussion improves the accu-
racy of clinical TNM stage allocation and ensures that
correct management decisions are applied to patients with
gastro-oesophageal cancer [109]. The MDT meeting may
also allow the preoperative staging imaging to be com-
pared with the histopathological report or images and this
feedback facilitates training, audit and teaching.
Conclusion
Accurate assessment of endoscopic biopsy material is cru-
cial in the assessment of patients with Barrett's oesopha-
gus. As appropriate care of patients with HGD in the
setting of Barrett's oesophagus relies heavily on the accu-
racy of reporting the degree of dysplasia, standardised
methods and guidelines should be followed.
The classification and staging systems for GOJ tumours
need to be improved and future research into this area is
greatly warranted. A better understanding of the clinical
relevance of each classification system for GOJ tumours
needs to be achieved before a final recommendation is
made. Although the Siewert classification has been shown
to have some clinical relevance, other authors have found
that it unnecessarily complicates the assessment of these
tumours and is fraught with difficulties because of the
overlapping nature of tumours in this region. Some
authors would argue that instead of three staging systems,
only two are required (with a staging system optimised
against current criticisms for oesophageal and GOJ
tumours and a separate staging system for gastric
tumours). Further clinical studies to address these issues
are urgently required.
There is already sufficient evidence to confirm that CRM
involvement is a marker of poor prognosis in oesophageal
cancer. As such, CRM status must continue to be routinely
reported. However, our understanding of its full signifi-
cance is limited compared to the field of rectal cancer
where CRM has been extensively studied. For example,
studies have been carried out directly comparing his-
topathological sections with preoperative cross-sectional
imaging. In rectal cancer, this information has been used
to predict potential CRM involvement prior to surgery
and thus the need for neo-adjuvant therapy. In future
oesophageal studies, especially prospective trials involv-
ing neo-adjuvant therapy or the comparison of different
surgical techniques, it is imperative that involvement of
the CRM is analysed.
There are exciting new research opportunities in the iden-
tification of lymph node micrometastases and sentinel
node involvement; however they have yet to be proven
clinically useful. There is emerging evidence that the his-
topathological evaluation of the tumour response to neo-
adjuvant therapy is prognostically relevant. However, fur-
ther research studies are required to confirm its role inWorld Journal of Surgical Oncology 2006, 4:82 http://www.wjso.com/content/4/1/82
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patient management. Although several classification sys-
tems have been devised they have yet to be agreed for rou-
tine clinical use. A standardised classification system for
the assessment of residual tumour burden after neo-adju-
vant therapy will need to be agreed and ideally adopted
internationally.
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